In the EAGLE-1 Phase III trial, gepotidacin met the primary efficacy endpoint of non-inferiorty to the current leading treatment for uncomplicated urogenital gonorrhea.
GSK Reports Promising Results from Clinical Trial of Oral Antibiotic for Uncomplicated Urogenital Gonorrhea.